Latest news
Grace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver QuantitativeQuiver Quantitative · Tue, 28 Jul 2026 07:00:00 GMTGrace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock TitanStock Titan · Tue, 28 Jul 2026 07:00:00 GMT